VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Classical swine fever virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Host Ranges and Animal Models
  2. Vaccine Related Pathogen Genes
    1. E0 (Protective antigen)
    2. E2 (Protective antigen)
    3. E2 (Protective antigen)
    4. gp55 (Protective antigen)
    5. E(rns) (Virmugen)
    6. E1 (Virmugen)
    7. E2 (Virmugen, Protective antigen)
  3. Vaccine Information
    1. Bayovac CSF E2
    2. Classical Swine Fever Virus DNA Vaccine pcDNA/E2 with TRIF
    3. Classical swine fever virus DNA vaccine pCI-gp55
    4. Classical swine fever virus E(rns) mutant vaccine
    5. Classical swine fever virus E1 mutant vaccine
    6. Classical swine fever virus E1 protein vaccine
    7. Classical swine fever virus E2 mutant vaccine
    8. Classical swine fever virus vaccine VAC-E0
    9. Classical swine fever virus vaccine VAC-E2
    10. DNA vaccine expressing the E2 protein
    11. Porcilis Pesti
    12. rAdV-SFV-E2
    13. rORFV-CSFV-E2
    14. rPFV-CSFV-E0
  4. References
I. General Information
1. NCBI Taxonomy ID:
11096
2. Disease:
Classical swine fever, hog cholera
3. Introduction
CSFV is closely related to the ruminant pestiviruses which cause Bovine Viral Diarrhoea (BVDV) and Border Disease (BDV). The effect of different CSFV strains varies widely, leading to a wide range of symptoms. Highly virulent strains correlate with acute, obvious disease and high mortality, including neurological symptoms and hemorrhages within the skin.

Less virulent strains can give rise to subacute or chronic infections that may escape detection, while still inducing mortality in fetuses and neonates. Infected piglets birthed from infected but subclinical sows help maintain the disease within a population. Other symptoms can include lethargy, fever, immunosuppression and secondary respiratory infections. The incubation period of CSFV ranges from 2 to 14 days, but symptoms may not be apparent until after 2 to 4 weeks. Animals with an acute infection can survive 2 to 3 months before their eventual death.

Eradicating CSF is problematic. Current programmes revolve around rapid detection and diagnosis, and preventive culling, possibly followed by emergency vaccination (ATCvet codes: QI09AA06 for the inactivated viral vaccine, QI09AD04 for the live vaccine). Possible sources for maintaining and introducing infection include the wide transport of pigs and pork products, as well as endemic CSF within wild boar and feral pig populations (Wiki: Classical swine fever).
4. Host Ranges and Animal Models
Swine fever is is a highly contagious disease of pigs and wild boar (Wiki: Classical swine fever).
1. E(rns)
  • Gene Name : E(rns)
  • Sequence Strain (Species/Organism) : Classical swine fever virus - Brescia
  • NCBI Protein GI : 130457
  • Other Database IDs : CDD:147625
    CDD:152325
    CDD:185828
    CDD:29472
    CDD:152822
    CDD:114308
    CDD:31829
    CDD:28927
    CDD:73158
  • Taxonomy ID : 11098
  • Gene Strand (Orientation) : ?
  • Protein Name : Genome polyprotein
  • Protein Note : N-terminal protease (By similarity). /FTId=PRO_0000038062.
  • Protein Sequence : Show Sequence 
    >gi|130457|sp|P21530.1|POLG_CSFVB RecName: Full=Genome polyprotein; Contains: RecName: Full=N-terminal protease; Short=N-pro; AltName: Full=Autoprotease p20; Contains: RecName: Full=Capsid protein C; Contains: RecName: Full=E(rns) glycoprotein; AltName: Full=gp44/48; Contains: RecName: Full=Envelope glycoprotein E1; AltName: Full=gp33; Contains: RecName: Full=Envelope glycoprotein E2; AltName: Full=gp55; Contains: RecName: Full=p7; Contains: RecName: Full=Non-structural protein 2-3; Short=NS2-3; Contains: RecName: Full=Cysteine protease NS2; AltName: Full=Non-structural protein 2; Contains: RecName: Full=Serine protease NS3; AltName: Full=Non-structural protein 3; Contains: RecName: Full=Non-structural protein 4A; Short=NS4A; Contains: RecName: Full=Non-structural protein 4B; Short=NS4B; Contains: RecName: Full=Non-structural protein 5A; Short=NS5A; Contains: RecName: Full=RNA-directed RNA polymerase; AltName: Full=NS5B
MELNHFELLYKTNKQKPMGVEEPVYDVTGRPLFGDPSEVHPQSTLKLPHDRGRGNIKTTLKNLPRRGDCR
SGNHLGPVSGIYVKPGPVFYQDYMGPVYHRAPLEFFDEAQFCEVTKRIGRVTGSDGKLYHIYVCIDGCIL
LKLAKRGEPRTLKWIRNLTDCPLWVTSCSDDGASASKEKKPDRINKGKLKIAPKEHEKDSRTKPPDATIV
VEGVKYQVKKKGKVKGKNTQDGLYHNKNKPPESRKKLEKALLAWAVIAIMLYQPVAAENITQWNLRDNGT
NGIQHAMYLRGVSRSLHGIWPEKICKGVPTYLATDTELREIQGMMVASEGTNYTCCKLQRHEWNKHGWCN
WYNIDPWIQLMNRTQANLAEGPPSKECAVTCRYDKNADINVVTQARNRPTTLTGCKKGTNFSFAGTVIEG
PCNFNVSVEDILYGDHECGSLLQDTALYLVDGMTNTIERARQGAARVTSWLGRQLRIAGKRLEGRSKTWF
GAYALSPYCNVTTKIGYIWYTNNCTPACLPKNTKIIGPGKFDTNAEDGKILHEMGGHLSEFLLLSLVVLS
DFAPETASALYLILHYVIPQSHEEPEGCDTNQLNLTVELRTEDVIPSSVWNVGKYVCVRPDWWPYETKVA
LLFEEAGQVVKLALRALRDLTRVWNSASTTAFLICLIKVLRGQVVQGVIWLLLVTGAQGRLACKEDHRYA
ISTTNEIGLHGAEGLTTTWKEYNHNLQLDDGTVKAICMAGSFKVTALNVVSRRYLASLHKDALPTSVTFE
LLFDGTSPLTEEMGDDFGFGLCPYDTSPVVKGKYNTTLLNGSAFYLVCPIGWTGVIECTAVSPTTLRTEV
VKTFRREKPFPYRRDCVTTTVENEDLFYCKWGGNWTCVKGEPVTYTGGPVKQCRWCGFDFNEPDGLPHYP
IGKCILANETGYRIVDSTDCNRDGVVISTEGSHECLIGNTTVKVHALDERLGPMPCRPKEIVSSAGPVRK
TSCTFNYAKTLRNRYYEPRDSYFQQYMLKGEYQYWFDLDVTDRHSDYFAEFIVLVVVALLGGRYVLWLIV
TYIVLTEQLAAGLQLGQGEVVLIGNLITHTDIEVVVYFLLLYLVMRDEPIKKWILLLFHAMTNNPVKTIT
VALLMVSGVAKGGKIDGGWQRLPETNFDIQLALTVIVVAVMLLAKKDPTTVPLVITVATLRTAKITNGLS
TDLAIATVSTALLTWTYISDYYKYKTLLQYLISTVTGIFLIRVLKGVGELDLHTPTLPSYRPLFFILVYL
ISTAVVTRWNLDIAGLLLQCVPTLLMVFTMWADILTLILILPTYELTKLYYLKEVKIGAERGWLWKTNFK
RVNDIYEVDQAGEGVYLFPSKQKTGTITGTMLPLIKAILISCISNKWQFIYLLYLIFEVSYYLHKKIIDE
IAGGTNFISRLVAALIEANWAFDNEEVRGLKKFFLLSSRVKELIIKHKVRNEVMVHWFGDEEVYGMPKLV
GLVKAATLSKNKHCILCTVCENREWRGETCPKCGRFGPPVTCGMTLADFEEKHYKRIFFREDQSEGPVRE
EYAGYLQYRARGQLFLRNLPVLATKVKMLLVGNLGTEVGDLEHLGWVLRGPAVCKKVTEHEKCTTSIMDK
LTAFFGVMPRGTTPRAPVRFPTSLLKIRRGLETGWAYTHQGGISSVDHVTCGKDLLVCDTMGRTRVVCQS
NNKMTDESEYGVKTDSGCPEGARCYVFNREAVNISGTKGAMVHLQKTGGEFTCVTASGTPAFFDLKNLKG
WSGLPIFEASSGRVVGRVKVGKNEDSKPTKLMSGIQTVSKSTTDLTEMVKKITTMNRGEFRQITLATGAG
KTTELPRSVIEEIGRHKRVLVLIPLRAAAESVYQYMRQKHPSIAFNLRIGEMKEGDMATGITYASYGYFC
QMPQPKLRAAMVEYSFIFLDEYHCSTPEQLAIMGKIHRFSENLRVVAMTATPAGTVTTTGQKHPIEEYIA
PEVMKGEDLGPEYLDIAGLKIPVEEMKSNMLVFVPTRNMAVETAKKLKAKGYNSGYYYSGEDPSNLRVVT
SQSPYVVVATNAIESGVTLPDLDVVVDTGLKCEKRIRLSPKMPFIVTGLKRMAVTIGEQAQRRGRVGRVK
PGRYYRSQETPVGSKDYHYDLLQAQRYGIEDGINITKSFREMNYDWSLYEEDSLMITQLEILNNLLISEE
LPMAVKNIMARTDHPEPIQLAYNSYETQVPVLFPKIKNGEVTDSYDNYTFLNARKLGDDVPPYVYATEDE
DLAVELLGLDWPDPGNQGTVEAGRALKQVVGLSTAENALLVALFGYVGYQALSKRHIPVVTDIYSIEDHR
LEDTTHLQYAPNAIKTEGKETELKELAQGDVQRCMEAMTNYARDGIQFMKSQALKVKETPTYKETMDTVA
DYVKKFMEALADSKEDIIKYGLWGTHTALYKSIGARLGNETAFATLVVKWLAFGGESIADHVKQAATDLV
VYYIINRPQFPGDTETQQEGRKFVASLLVSALATYTYKSWNYNNLSKIVEPALATLPYAATALKLFAPTR
LESVVILSTAIYKTYLSIRRGKSDGLLGTGVSAAMEIMSQNPVSVGIAVMLGVGAVAAHNAIEASEQKRT
LLMKVFVKNFLDQAATDELVKESPEKIIMALFEAVQTVGNPLRLVYHVYGVFYKGWEAKELAQRTAGRNL
FTLIMFEAVELLGVDSEGKIRQLSSNYILELLYKFRDSIKSSVRQMAISWAPAPFSCDWTPTDDRIGLPQ
DNFLRVETKCPCGYKMKAVKNCAGELRLLEEEGSFLCRNKFGRGSRNYRVTKYYDDNLSEIKPVIRMEGH
VELYYKGATIKLDFNNSKTILATDKWEVDHSTLVRVLKRHTGAGYCGAYLGEKPNHKHLIERDCATITKD
KVCFLKMKRGCAFTYDLSLHNLTRLIELVHKNNLEDKEIPAVTVTTWLAYTFVNEDIGTIKPAFGEKITP
EMQEEITLQPAVLVDATDVTVTVVGETPTMTTGETPTTFTSSGPDPKGQQVLKLGVGEGQYPGTNPQRAS
LHEAIQSADERPSVLILGSDKATSNRVKTVKNVKVYRGRDPLEVRDMMRRGKILVIALSRVDNALLKFVD
YKGTFLTRETLEALSLGRPKKKNITKAEAQWLLRLEDQMEELPDWFAAGEPIFLEANIKHDRYHLVGDIA
TIKEKAKQLGATDSTKISKEVGAKVYSMKLSNWVMQEENKQSNLTPLFEELLQQCPPGGQNKTAHMVSAY
QLAQGNWMPTSCHVFMGTISARRTKTHPYEAYVKLRELVEEHKMKTLCPGSSLRNDNEWVIGKIKYQGNL
RTKHMLNPGKVAEQLHREGHRHNVYNKTIGSVMTATGIRLEKLPVVRAQTDTTNFHQAIRDKIDKEENLQ
TPGLHKKLMEVFNALKRPELESSYDAVEWEELERGINRKGAAGFFERKNIGEILDSEKIKVEEIIDNLKK
GRNIKYYETAIPKNEKRDVNDDWTAGDFVDEKKPRVIQYPEAKTRLAITKVMYKWVKQKPVVIPGYEGKT
PLFQIFDKVKKEWDQFQNPVAVSFDTKAWDTQVTTNDLELIKDIQKYYFKKKWHKFIDTLTMHMSEVPVI
TADGEVYIRKGQRGSGQPDTSAGNSMLNVLTMVYAFCEATGVPYKSFDRVAKIHVCGDDGFLITERALGE
KFASKGVQILYEAGKPQKITEGDKMKVAYQFADIEFCSHTPIQVRWSDNTSSYMPGRNTTTILAKMATRL
DSSGERGTIAYEKAVAFSFLLMYSWNPLIRRICLLVLSTELQVKPGKSTTYYYEGDPISAYKEVIGHNLF
DLKRTSFEKLAKLNLSMSVLGAWTRHTSKRLLQDCVNMGVKEGNWLVNADRLVSSKTGNRYVPGEGHTLQ
GRHYEELALARKQINSFQGTDRYNLGPIVNMVLRRLRVMMMTLIGRGV
  • Molecule Role : Virmugen
  • Molecule Role Annotation : An N269A/Q mutation in the E(rns) protein created an attenuated mutant in swine. This mutant was able to induce effective protection in swine against challenge with wild type CSFV (Sainz et al., 2008).
  • Related Vaccine(s): Classical swine fever virus E(rns) mutant vaccine
2. E0
  • Gene Name : E0
  • VO ID : VO_0010898
  • NCBI Protein GI : 115343287
  • Other Database IDs : CDD:294141
    CDD:238220
  • Taxonomy ID : 11096
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein E0
  • Protein pI : 7.85
  • Protein Weight : 25600.45
  • Protein Length : 313
  • Protein Note : Ribonuclease T2 (RNase T2) is a widespread family of secreted RNases found in every organism examined thus far. This family includes RNase Rh, RNase MC1, RNase LE, and self-incompatibility RNases (S-RNases). Plant T2 RNases are expressed during leaf...; cl00208
  • Protein Sequence : Show Sequence 
    >ABI94604.1 envelope glycoprotein E0, partial [Classical swine fever virus]
ENITQWNLSDNGTNGIQRAMYLRGVNRSLHGIWPEKICKGVPTHLATDTELTEIRGMMDASERTNYTCCR
LQRHEWNKHGWCNWYNVDPWIQLMNRTQANLTEGPSDKECAVTCRYDRNADVNVVTQARNRPTTLTGCRK
GKNFSFAGTVIEGPCNFNVSVEDILYGDHECGSLLQDTALYLLDGMTNTIENARQGAARVTSWLGRQLST
AGKKLERRSKTWFGAYALSPYC
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).
  • Related Vaccine(s): Classical swine fever virus vaccine VAC-E0 , rPFV-CSFV-E0
3. E1
  • Gene Name : E1
  • Sequence Strain (Species/Organism) : Classical swine fever virus - Brescia
  • NCBI Nucleotide GI : 325460
  • NCBI Protein GI : 325461
  • Protein Accession : AAA43843.1
  • Taxonomy ID : 11098
  • Gene Strand (Orientation) : ?
  • Protein Name : envelope glycoprotein E1
  • DNA Sequence : Show Sequence 
    >gi|325460|gb|M31768.1|HCVCG3PE Classical swine fever virus - Brescia hog cholera virus protein precursor, gene, complete cds
AGTTCATTCTCGTGTACATGATTGGACAAATCAAAATCTCAATTTGGTTCAGGGCCTCCCTCCAGCGACG
GCCGAGCTGGGCTAGCCATGCCCACAGTAGGACTAGCAAACGGAGGGACTAGCCGTAGTGGCGAGCTCCC
TGGGTGGTCTAAGTCCTGAGTACAGGACAGTCGTCAGTAGTTCGACGTGAGCAGAAGCCCACCTCGAGAT
GCTATGTGGACGAGGGCATGCCCAAGACACACCTTAACCTAGCGGGGGTCGTTAGGGTGAAATCACACCA
TGTGATGGGAGTACGACCTGATAGGGTGCTGCAGAGGCCCACTATTAGGCTAGTATAAAAATCTCTGCTG
TACATGGCACATGGAGTTGAATCATTTTGAACTTTTATACAAAACAAACAAACAAAAACCAATGGGAGTG
GAGGAACCGGTATACGATGTAACGGGGAGACCATTGTTTGGAGACCCAAGTGAGGTACACCCACAATCAA
CATTGAAGCTACCACATGATAGGGGGAGAGGCAACATCAAAACAACACTGAAGAATCTACCTAGGAGAGG
TGACTGCAGGAGTGGCAACCACCTAGGCCCGGTTAGTGGGATATATGTAAAGCCCGGCCCTGTCTTTTAT
CAGGACTACATGGGCCCAGTCTATCATAGAGCCCCTCTGGAGTTTTTTGACGAAGCACAGTTCTGTGAGG
TGACCAAAAGGATAGGTAGGGTGACAGGTAGTGACGGAAAGCTTTACCATATATACGTGTGCATCGATGG
TTGCATCCTGCTGAAGCTAGCCAAGAGGGGCGAGCCAAGAACCCTGAAGTGGATTAGAAATCTCACCGAC
TGTCCATTGTGGGTTACCAGTTGTTCTGATGATGGTGCAAGTGCAAGTAAAGAGAAGAAACCAGATAGGA
TCAACAAGGGTAAATTAAAGATAGCCCCAAAAGAGCATGAGAAGGACAGCAGGACTAAGCCACCTGATGC
TACGATTGTAGTGGAAGGAGTAAAATACCAGGTCAAAAAGAAAGGTAAAGTTAAGGGAAAGAATACCCAA
GACGGCCTGTACCACAACAAGAATAAACCACCAGAATCTAGGAAGAAATTAGAAAAAGCCCTATTGGCAT
GGGCAGTGATAGCAATTATGTTATACCAACCTGTTGCAGCCGAAAATATAACTCAATGGAACCTGAGAGA
CAACGGTACCAATGGTATCCAGCACGCTATGTACCTTAGAGGAGTCAGCAGAAGCTTGCATGGGATCTGG
CCAGAAAAAATATGCAAAGGAGTCCCCACCTACCTGGCCACAGACACGGAACTGAGAGAAATACAGGGAA
TGATGGTAGCCAGCGAGGGGACAAACTATACGTGCTGTAAGTTACAGAGACATGAATGGAACAAACATGG
ATGGTGTAACTGGTATAACATAGACCCCTGGATACAGTTAATGAATAGAACCCAAGCAAACTTGGCAGAA
GGCCCTCCGAGCAAGGAGTGCGCCGTGACTTGCAGGTACGATAAAAATGCTGACATTAACGTGGTCACCC
AGGCCAGAAACAGGCCAACCACCCTAACTGGCTGCAAGAAAGGGACCAATTTTTCTTTTGCGGGTACAGT
TATAGAGGGCCCATGTAATTTCAACGTTTCTGTCGAGGATATCTTATATGGGGATCATGAGTGTGGCAGT
CTACTCCAGGATACGGCTCTATACCTAGTAGATGGAATGACCAACACTATAGAGAGAGCCAGGCAGGGAG
CCGCGAGGGTGACATCTTGGCTAGGGAGGCAACTCCGCATTGCCGGGAAGAGGTTGGAGGGCAGAAGCAA
AACCTGGTTTGGTGCCTATGCCCTATCACCTTATTGTAATGTGACAACGAAAATAGGGTACATATGGTAC
ACTAACAACTGTACCCCGGCTTGCCTCCCCAAAAATACAAAGATAATAGGCCCCGGTAAATTTGACACTA
ACGCGGAAGACGGAAAGATTCTCCATGAGATGGGGGGCCACCTATCAGAATTTCTGCTGCTCTCTCTGGT
CGTTCTGTCTGACTTCGCCCCTGAAACAGCCAGCGCGTTATACCTCATTTTGCACTACGTGATCCCTCAA
TCCCATGAAGAACCTGAAGGCTGTGACACAAACCAGCTGAATTTAACAGTGGAACTCAGGACTGAAGACG
TGATACCATCATCAGTCTGGAATGTTGGCAAATATGTGTGTGTTAGACCAGACTGGTGGCCATATGAAAC
CAAGGTGGCTTTGTTATTTGAAGAGGCAGGACAGGTCGTAAAGTTAGCCTTGCGGGCACTGAGGGATTTA
ACCAGGGTCTGGAATAGCGCATCAACCACGGCATTCCTCATCTGCTTGATAAAAGTATTAAGAGGACAGG
TCGTGCAAGGTGTGATATGGCTGTTACTGGTAACTGGGGCACAAGGCCGGCTAGCCTGCAAGGAAGATCA
CAGGTACGCTATATCAACAACCAATGAGATAGGGCTACATGGGGCCGAAGGTCTCACTACCACCTGGAAA
GAATACAACCACAATTTGCAACTGGATGATGGGACCGTCAAGGCCATCTGCATGGCAGGTTCCTTTAAAG
TCACAGCACTTAATGTGGTTAGTAGGAGGTATCTGGCATCATTACATAAGGACGCTTTACCCACTTCCGT
GACATTCGAGCTCCTGTTCGACGGGACCAGCCCATTGACCGAGGAAATGGGAGATGACTTCGGGTTCGGA
CTGTGTCCGTATGATACGAGCCCTGTAGTCAAGGGAAAATACAACACAACCTTGTTGAATGGTAGTGCAT
TCTACCTAGTTTGCCCAATAGGGTGGACGGGTGTTATAGAGTGCACGGCAGTGAGCCCGACAACTCTGAG
AACAGAAGTGGTAAAGACCTTCAGAAGAGAGAAACCCTTTCCGTACAGAAGGGATTGTGTGACCACTACA
GTGGAAAATGAAGATCTATTCTACTGTAAATGGGGGGGCAATTGGACATGTGTGAAAGGTGAACCAGTGA
CCTACACGGGGGGGCCAGTAAAACAATGCAGATGGTGTGGCTTCGACTTCAATGAGCCTGACGGACTCCC
ACACTACCCCATAGGTAAGTGCATTTTGGCAAATGAGACAGGTTACAGAATAGTGGATTCAACGGACTGT
AACAGAGATGGCGTTGTAATCAGCACAGAGGGGAGTCATGAGTGCTTGATTGGTAACACAACTGTCAAGG
TGCATGCATTAGATGAAAGACTAGGCCCTATGCCATGCAGGCCTAAGGAGATCGTCTCTAGTGCGGGACC
TGTAAGGAAAACTTCCTGTACATTCAACTACGCAAAAACTCTGAGGAACAGGTATTATGAGCCCAGGGAC
AGCTATTTCCAACAATATATGCTCAAGGGCGAGTATCAGTACTGGTTTGATCTGGATGTGACCGACCGCC
ACTCAGATTACTTCGCAGAATTCATTGTCTTGGTGGTGGTGGCACTGTTGGGAGGAAGATATGTCCTGTG
GCTAATAGTGACCTACATAGTTCTAACAGAACAACTCGCCGCTGGTCTACAGTTAGGCCAGGGTGAGGTA
GTGTTAATAGGGAACTTAATCACCCACACAGATATTGAGGTTGTAGTATATTTCTTACTGCTCTATTTGG
TCATGAGAGATGAGCCTATAAAGAAATGGATACTACTGCTGTTCCATGCTATGACCAACAATCCAGTTAA
GACCATAACAGTGGCACTGCTCATGGTTAGCGGGGTTGCCAAGGGTGGAAAGATAGATGGTGGTTGGCAG
CGGCTGCCGGAGACCAACTTTGATATCCAACTCGCGCTGACAGTTATAGTAGTCGCTGTGATGTTGCTGG
CAAAGAAAGATCCGACTACCGTCCCCTTGGTTATAACGGTGGCAACCCTGAGAACGGCTAAGATAACTAA
TGGACTTAGTACAGATCTAGCCATAGCTACAGTGTCAACAGCTTTGCTAACCTGGACCTACATTAGTGAC
TATTATAAATACAAGACCTTGCTACAGTACCTTATTAGCACAGTGACAGGTATCTTCTTGATAAGGGTAC
TGAAGGGGGTAGGTGAGTTAGATTTACACACCCCAACCTTACCATCTTACAGACCCCTCTTCTTCATCCT
CGTGTACCTCATTTCCACTGCAGTGGTAACAAGATGGAATCTGGACATAGCCGGATTGCTGCTGCAGTGT
GTCCCAACCCTTTTAATGGTTTTCACGATGTGGGCAGACATCCTTACCCTGATCCTCATACTGCCTACTT
ACGAGTTGACAAAACTATATTACCTCAAGGAAGTGAAGATTGGGGCAGAAAGGGGCTGGTTGTGGAAGAC
CAACTTCAAGAGGGTAAATGACATATACGAAGTTGACCAAGCTGGTGAGGGGGTGTACCTTTTCCCATCA
AAACAAAAGACAGGTACAATAACAGGTACTATGTTGCCACTGATCAAAGCCATACTCATAAGTTGCATCA
GCAATAAGTGGCAATTTATATATCTATTGTACTTGATATTCGAAGTGTCTTACTACCTTCACAAGAAGAT
CATAGATGAAATAGCAGGAGGGACCAACTTCATCTCGAGACTTGTAGCCGCTCTGATCGAAGCCAATTGG
GCCTTTGACAACGAAGAAGTTAGAGGTTTAAAGAAGTTCTTCTTGCTGTCTAGTAGGGTTAAAGAACTGA
TCATCAAACACAAAGTGAGGAATGAAGTGATGGTCCACTGGTTTGGCGACGAAGAGGTCTATGGGATGCC
GAAGCTGGTTGGCTTAGTCAAGGCAGCAACACTGAGTAAAAATAAACATTGTATTTTGTGCACCGTCTGT
GAAAACAGAGAGTGGAGAGGAGAAACCTGCCCAAAATGCGGCCGTTTTGGGCCACCAGTGACCTGTGGCA
TGACCCTAGCCGACTTTGAAGAAAAACACTATAAGAGGATTTTCTTTAGAGAGGATCAATCAGAAGGGCC
GGTTAGGGAGGAGTATGCAGGGTATCTGCAATATAGAGCCAGAGGGCAATTATTCCTGAGGAATCTCCCG
GTGCTAGCAACAAAAGTCAAGATGCTCCTGGTCGGAAATCTTGGGACGGAGGTGGGGGATTTGGAACACC
TTGGCTGGGTGCTCAGAGGGCCTGCCGTTTGCAAGAAGGTTACCGAACATGAGAAATGCACCACATCCAT
AATGGACAAATTAACTGCTTTCTTCGGTGTTATGCCAAGGGGCACCACACCTAGAGCCCCTGTGAGATTC
CCCACCTCTCTCTTAAAGATAAGAAGGGGGCTGGAAACTGGCTGGGCGTACACACACCAAGGTGGCATCA
GTTCAGTGGACCATGTCACTTGTGGGAAAGACTTACTGGTATGTGACACTATGGGCCGGACAAGGGTTGT
TTGCCAATCAAATAACAAGATGACAGACGAGTCCGAGTATGGAGTTAAAACTGACTCCGGATGCCCGGAG
GGAGCTAGGTGTTACGTGTTCAACCGAGAGGCAGTTAATATATCCGGGACTAAAGGAGCTATGGTCCACT
TACAAAAAACTGGAGGAGAATTCACCTGTGTGACAGCATCAGGGACTCCGGCCTTCTTTGATCTCAAGAA
CCTCAAAGGCTGGTCAGGGCTACCGATATTTGAGGCATCAAGTGGAAGAGTAGTCGGCAGGGTTAAGGTC
GGGAAGAATGAGGACTCTAAACCAACCAAGCTTATGAGTGGAATACAAACAGTCTCCAAAAGTACCACAG
ACTTGACAGAAATGGTAAAGAAAATAACAACCATGAACAGGGGAGAATTCAGACAAATAACCCTTGCCAC
AGGTGCCGGAAAAACCACGGAACTCCCTAGATCAGTCATAGAAGAGATAGGAAGGCATAAGAGGGTCTTG
GTCTTGATCCCTCTGAGGGCGGCAGCAGAGTCAGTATACCAATATATGAGACAAAAACACCCAAGCATAG
CATTCAACTTGAGGATAGGGGAGATGAAGGAAGGGGACATGGCCACAGGGATAACCTATGCCTCATATGG
TTACTTCTGTCAGATGCCACAACCTAAGCTGCGAGCCGCGATGGTTGAGTACTCCTTCATATTCCTTGAT
GAGTACCACTGTTCCACCCCCGAACAATTGGCTATCATGGGAAAGATCCACAGATTTTCAGAGAACCTGC
GGGTAGTAGCCATGACCGCAACACCAGCAGGCACGGTAACAACTACAGGGCAAAAACACCCTATAGAAGA
ATACATAGCCCCAGAAGTGATGAAGGGGGAAGACTTAGGTCCAGAGTACTTGGACATAGCTGGACTAAAG
ATACCAGTAGAGGAGATGAAGAGTAACATGCTGGTCTTTGTGCCCACAAGGAACATGGCTGTAGAGACGG
CAAAGAAACTGAAAGCTAAGGGTTATAACTCAGGCTACTATTATAGTGGAGAGGATCCATCTAACCTGAG
GGTGGTAACATCACAGTCCCCGTACGTGGTGGTAGCAACCAACGCAATAGAATCAGGTGTTACTCTCCCA
GACTTGGATGTGGTCGTCGACACAGGGCTTAAGTGTGAAAAGAGGATACGGCTGTCACCTAAGATGCCCT
TCATAGTGACGGGCCTGAAGAGAATGGCTGTCACGATTGGGGAACAAGCCCAGAGAAGGGGGAGAGTTGG
GAGAGTGAAGCCTGGGAGATACTACAGGAGTCAAGAAACCCCCGTTGGTTCCAAAGATTACCATTACGAC
CTACTGCAAGCACAGAGGTACGGTATAGAAGATGGGATAAACATCACCAAATCTTTTAGAGAGATGAATT
ATGATTGGAGCCTTTATGAGGAGGATAGTCTGATGATTACACAATTGGAAATCCTCAACAATCTGTTGAT
ATCAGAAGAGCTACCAATGGCAGTAAAAAATATAATGGCCAGGACTGACCACCCAGAACCAATCCAACTG
GCGTACAACAGCTACGAAACGCAGGTGCCAGTTCTATTCCCAAAAATAAAAAATGGAGAGGTGACTGACA
GTTACGATAACTATACCTTCCTCAACGCAAGAAAGCTGGGGGATGATGTACCACCCTACGTGTATGCCAC
AGAGGATGAGGACTTAGCGGTAGAGCTGCTGGGCTTAGACTGGCCGGACCCTGGGAACCAAGGAACCGTG
GAGGCTGGTAGAGCACTAAAACAAGTAGTTGGTCTATCAACAGCTGAGAACGCCCTGTTAGTAGCTTTAT
TCGGCTATGTAGGATATCAGGCACTCTCAAAGAGGCATATACCAGTAGTCACAGACATATATTCAATTGA
AGATCACAGGTTGGAAGACACCACACACCTACAGTATGCCCCGAATGCTATCAAGACGGAGGGGAAGGAG
ACAGAATTGAAGGAGCTAGCTCAGGGGGATGTGCAGAGATGTATGGAAGCTATGACTAATTATGCAAGAG
ATGGCATCCAATTCATGAAGTCTCAGGCACTGAAAGTGAAAGAAACCCCCACTTACAAAGAGACAATGGA
CACCGTGGCGGACTATGTAAAGAAGTTCATGGAGGCACTGGCGGACAGCAAAGAAGACATCATAAAATAT
GGGTTGTGGGGGACGCACACAGCCTTATATAAGAGCATCGGTGCTAGGCTTGGGAACGAGACTGCGTTCG
CTACCCTGGTCGTGAAATGGCTGGCATTTGGGGGAGAATCAATAGCAGACCATGTCAAACAAGCGGCCAC
AGACTTGGTCGTTTACTATATCATCAACAGACCTCAGTTCCCAGGAGACACGGAGACACAACAGGAAGGA
AGGAAATTTGTAGCCAGCCTACTGGTCTCAGCCCTGGCTACTTACACTTACAAAAGCTGGAATTACAATA
ATCTGTCCAAGATAGTTGAACCGGCTTTGGCTACTCTGCCCTATGCCGCCACAGCTCTCAAGCTATTCGC
CCCCACTCGATTGGAGAGCGTTGTCATACTGAGTACCGCAATCTACAAAACCTACCTATCAATCAGGCGC
GGAAAAAGCGATGGTTTGCTAGGCACAGGGGTTAGTGCGGCTATGGAAATCATGTCACAAAACCCAGTAT
CTGTGGGTATAGCGGTCATGCTAGGGGTGGGGGCCGTAGCGGCCCACAATGCAATCGAAGCCAGTGAGCA
GAAGAGAACACTACTCATGAAAGTTTTTGTAAAGAACTTCTTGGATCAGGCAGCCACTGATGAATTAGTC
AAGGAGAGCCCTGAGAAAATAATAATGGCTTTGTTTGAAGCAGTGCAGACAGTCGGCAACCCTCTTAGAC
TGGTATACCACGTTTACGGAGTTTTTTACAAAGGGTGGGAGGCAAAAGAGTTGGCCCAAAGGACAGCCGG
TAGGAATCTTTTCACTTTGATAATGTTTGAGGCTGTGGAACTACTGGGAGTAGATAGCGAAGGAAAGATC
CGCCAGCTATCAAGCAATTACATACTAGAGCTCCTGTATAAGTTCCGTGACAGTATCAAGTCCAGCGTGA
GGCAGATGGCAATCAGCTGGGCCCCTGCCCCTTTTAGTTGTGATTGGACACCGACGGATGACAGAATAGG
GCTTCCCCAAGATAATTTCCTCCGAGTGGAGACAAAATGCCCCTGTGGTTACAAGATGAAAGCAGTTAAG
AATTGTGCTGGGGAGTTGAGACTCTTAGAGGAGGAAGGCTCATTTCTCTGCAGGAATAAATTCGGGAGAG
GTTCACGGAACTACAGGGTGACAAAATACTATGATGACAATCTATCAGAAATAAAGCCAGTGATAAGAAT
GGAAGGACATGTGGAACTCTACTACAAGGGAGCCACTATTAAACTGGATTTCAACAACAGTAAAACAATA
TTGGCAACCGATAAATGGGAGGTCGATCACTCCACTCTGGTCAGGGTGCTCAAGAGGCACACAGGGGCTG
GATATTGTGGGGCATACCTGGGTGAGAAACCGAACCACAAACATCTGATAGAGAGGGACTGCGCAACCAT
CACCAAAGATAAGGTTTGTTTTCTCAAGATGAAGAGAGGGTGTGCATTTACTTATGACTTATCCCTTCAC
AACCTTACCCGGCTGATTGAATTGGTACACAAGAATAACTTGGAAGACAAAGAGATTCCTGCCGTTACGG
TCACAACCTGGCTGGCTTACACATTTGTAAATGAAGATATAGGGACCATAAAACCAGCCTTCGGGGAGAA
AATAACACCAGAGATGCAGGAGGAGATAACCTTGCAGCCTGCTGTATTGGTGGATGCAACTGACGTGACC
GTGACCGTGGTAGGGGAAACCCCTACTATGACTACAGGGGAGACCCCAACAACGTTCACCAGCTCAGGTC
CAGACCCGAAAGGCCAACAAGTTTTAAAACTGGGTGTAGGTGAAGGCCAATACCCCGGGACTAATCCACA
GAGAGCAAGCCTGCACGAAGCCATACAAAGCGCAGATGAAAGGCCCTCTGTGCTGATATTGGGGTCTGAT
AAAGCCACCTCTAATAGAGTGAAAACTGTAAAGAATGTGAAGGTATACAGAGGCAGGGACCCACTAGAAG
TGAGAGATATGATGAGGAGGGGAAAGATCCTAGTCATAGCCCTGTCTAGGGTTGATAATGCTCTATTGAA
ATTTGTAGATTACAAAGGCACCTTTTTAACTAGAGAGACCCTGGAGGCATTAAGTTTGGGTAGGCCAAAA
AAGAAAAACATAACCAAGGCAGAAGCACAGTGGTTGCTGCGCCTCGAAGACCAAATGGAAGAGCTACCCG
ATTGGTTCGCAGCCGGGGAACCCATTTTTCTAGAGGCCAATATTAAACATGACAGGTATCATCTGGTAGG
GGATATAGCTACTATCAAAGAGAAAGCCAAACAATTGGGGGCTACAGACTCTACAAAGATATCCAAGGAG
GTTGGTGCAAAAGTATATTCTATGAAATTGAGTAATTGGGTGATGCAAGAAGAAAACAAACAGAGCAACT
TGACCCCCTTATTTGAAGAGCTCCTACAGCAGTGTCCACCCGGAGGCCAAAACAAAACTGCACATATGGT
CTCTGCTTACCAACTAGCTCAAGGGAACTGGATGCCAACCAGCTGCCATGTTTTTATGGGGACCATATCT
GCCAGAAGGACTAAGACCCATCCATATGAAGCATATGTCAAGTTAAGGGAGTTGGTAGAGGAACACAAGA
TGAAAACATTGTGTCCCGGATCAAGTCTGCGTAACGACAATGAATGGGTAATTGGCAAGATCAAATACCA
GGGCAACCTGAGGACCAAACACATGTTGAACCCCGGCAAGGTGGCAGAGCAACTGCACAGAGAAGGACAC
AGACACAATGTGTATAACAAGACAATAGGCTCAGTGATGACAGCTACTGGCATCAGGTTGGAGAAGTTGC
CCGTGGTTAGGGCCCAGACAGACACAACCAACTTCCACCAAGCAATAAGGGATAAGATAGACAAGGAAGA
GAATCTACAGACCCCGGGTTTACATAAGAAACTAATGGAAGTTTTCAATGCATTGAAACGACCCGAGTTA
GAGTCCTCCTATGACGCTGTGGAATGGGAGGAATTGGAGAGAGGAATAAACAGAAAGGGTGCTGCTGGTT
TCTTTGAACGCAAAAACATAGGGGAGATATTGGATTCAGAGAAAATTAAAGTAGAAGAGATTATTGACAA
TCTGAAAAAGGGTAGAAATATCAAATACTATGAAACCGCAATCCCAAAAAATGAAAAGAGGGATGTCAAT
GATGACTGGACCGCAGGTGACTTTGTGGACGAGAAGAAACCCAGAGTCATACAATACCCTGAAGCAAAAA
CAAGGCTGGCCATCACCAAGGTGATGTATAAGTGGGTGAAGCAGAAGCCAGTAGTCATACCCGGGTATGA
AGGGAAGACACCTCTGTTCCAAATTTTTGACAAAGTAAAGAAGGAATGGGATCAATTCCAAAATCCAGTG
GCAGTGAGCTTCGACACTAAGGCGTGGGACACCCAGGTGACCACAAATGATCTGGAGCTGATAAAGGACA
TACAAAAGTACTACTTCAAGAAGAAATGGCATAAATTTATTGACACCCTGACTATGCATATGTCAGAAGT
ACCCGTAATCACTGCTGATGGGGAGGTGTATATAAGGAAAGGGCAAAGAGGTAGTGGACAGCCCGACACA
AGCGCAGGCAACAGCATGCTAAATGTGTTAACAATGGTTTATGCCTTCTGCGAGGCCACAGGGGTACCCT
ACAAGAGTTTTGACAGGGTGGCAAAAATTCATGTGTGTGGGGACGATGGTTTCCTGATCACAGAGAGAGC
TCTCGGCGAGAAATTCGCAAGCAAGGGAGTCCAAATCCTGTATGAAGCTGGGAAGCCCCAGAAGATCACT
GAAGGGGACAAAATGAAAGTGGCCTACCAATTTGCTGATATTGAGTTTTGCTCCCATACACCAATACAAG
TAAGGTGGTCAGATAACACTTCTAGCTACATGCCAGGGAGAAATACAACCACAATCCTGGCTAAAATGGC
CACAAGGTTAGATTCCAGTGGTGAGAGGGGTACCATAGCGTACGAGAAAGCAGTAGCATTCAGCTTCCTG
CTAATGTATTCCTGGAACCCACTAATCAGAAGGATTTGCTTATTGGTACTATCAACTGAACTGCAAGTGA
AACCAGGGAAGTCAACCACTTACTATTATGAAGGGGACCCGATATCTGCCTACAAGGAAGTCATCGGCCA
CAATCTTTTCGATCTCAAGAGAACAAGCTTCGAGAAGCTGGCCAAGTTAAATCTCAGCATGTCCGTACTC
GGGGCCTGGACTAGACACACCAGCAAAAGACTACTACAAGACTGTGTCAATATGGGTGTTAAAGAGGGCA
ACTGGTTAGTCAATGCAGACAGACTGGTGAGTAGTAAGACTGGAAATAGGTATGTACCTGGAGAAGGCCA
CACCCTGCAAGGGAGACATTATGAAGAACTGGCGTTGGCAAGAAAACAGATCAACAGCTTCCAAGGGACA
GACAGGTACAATCTAGGCCCAATAGTCAACATGGTGTTAAGGAGGCTGAGAGTCATGATGATGACCCTGA
TAGGGAGAGGGGTATGAGTGCGGGTGACCCGCGATCTGGACCCGTCAGTAGGACCCTATTGTAGATAACA
CTAATTTTTTATTTATTTAGATATTACTATTTATTTATTTATTTATTTATTGAATGAGTAAGAACTGGTA
CAAACTACCTCATGTTACCACACTACACTCATTTTAACAGCACTTTAGCTGGAAGGAAAATTCCTGACGT
CCACAGTTGGACTAAGGTAATTTCTAACGGCCC
  • Molecule Role : Virmugen
  • Molecule Role Annotation : An N to A amino acid substitution was made in the N594 site of the E1 glycoprotein, resulting in attenuation of the virus in swine. This attenuated virus induced protection against challenge with wild type CSFV (Fernandez-Sainz et al., 2009).
  • Related Vaccine(s): Classical swine fever virus E1 mutant vaccine
4. E2
  • Gene Name : E2
  • Sequence Strain (Species/Organism) : Classical swine fever virus strain LPC
  • VO ID : VO_0010897
  • NCBI Protein GI : 50403916
  • Other Database IDs : CDD:292945
  • Taxonomy ID : 11096
  • Gene Starting Position : 373
  • Gene Ending Position : 12069
  • Gene Strand (Orientation) : +
  • Protein Name : E2 protein
  • Protein pI : 8.23
  • Protein Weight : 6837.14
  • Protein Length : 127
  • Protein Note : Pestivirus envelope glycoprotein E2; pfam16329
  • Protein Sequence : Show Sequence 
    >AAT76713.1 E2 protein, partial [Classical swine fever virus]
TTTWKEYTHDLQLNDGTVKATCVAGSFKVTALNVVSRRYLASLHKKALPTSVTFELLFDGTNP
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Pigs were subjected to challenge infection with a dose of 1x10(5)TCID(50) (50% tissue culture infective dose) virulent CSFV strain. At 1 week post challenge infection, all of the yE2-immunized pigs were alive and without symptoms or signs of CSF. The yeast-expressed E2 protein retains correct immunogenicity and is able to induce a protective immune response against CSFV infection (Lin et al., 2009).

    In a seperate study, swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).
  • Related Vaccine(s): Classical swine fever virus vaccine VAC-E2 , rAdV-SFV-E2
5. E2
  • Gene Name : E2
  • Sequence Strain (Species/Organism) : Classical swine fever virus
  • NCBI Gene ID : 920146
  • NCBI Protein GI : 12657942
  • Locus Tag : PestiV2gp1
  • Genbank Accession : AF326963
  • Protein Accession : NP_075354
  • Taxonomy ID : 11096
  • Gene Starting Position : 373
  • Gene Ending Position : 12069
  • Gene Strand (Orientation) : +
  • Protein Name : polyprotein
  • Protein pI : 8.53
  • Protein Weight : 408166.02
  • Protein Length : 3898
  • DNA Sequence : Show Sequence 
    >NC_002657.1:373-12069 Classical swine fever virus, complete genome
CATGGAGTTGAATCATTTTGAACTTTTATACAAAACAAACAAACAAAAACCAATGGGAGTGGAGGAACCG
GTATACGATGCCACGGGGAGGCCATTGTTTGGAGACCCGAGTGAGGTACACCCACAATCAACACTGAAGC
TACCACATGATAGGGGGAGAGGTAACATCAAAACAACACTGAAGAACCTACCTAGGAAAGGCGACTGCAG
GAGTGGCAACCATCTAGGCCCGGTTAGTGGGATATATGTAAAGCCCGGCCCTGTCTTTTATCAGGACTAC
ATGGGCCCGGTCTACCATAGAGCCCCTCTAGAGTTTTTTAACGAAGCGCAGTTTTGCGAGGTGACCAAAA
GGATAGGTAGGGTGACAGGTAGTGACGGAAAGCTTTACCATATATATGTGTGCATCGATGGTTGCATACT
GCTGAAGCTAGCCAAGAGGGACGAGCCAAGAACCCTGAAGTGGATTAGAAATTTCACCGACTGTCCATTG
TGGGTTACCAGTTGCTCTGATGATGGCGCAAGTGGAAGTAAAGAGAAGAAGCCAGATAGGATCAACAAAG
GCAAATTAAAAATAGCCCCAAAAGAGCATGAGAAGGACAGCAGAACTAAGCCACCTGACGCTACGATTGT
AGTGGAAGGAGTAAAATACCAGGTTAAAAAGAAGGGTAAAGTTAAAGGAAAGAGTACCCAAGACGGCCTG
TACCACAACAAGAATAAACCACCAGAATCTAGGAAGAAATTAGAAAAAGCCCTATTGGCATGGGCGGTAA
TAGCAATTATGTTGTACCAACCAGTTGAAGCCGAAAATATAACTCAATGGAACCTGAGTGACAACGGCAC
TAATGGTATCCAGCATGCTATGTACCTTAGAGGGGTTAGCAGGAGCTTGCATGGGATCTGGCCGGAAAAA
ATATGCAAAGGAGTCCCCACCTACCTGGCCACAGACACGGAACTGAAAGAAATACAGGGAATGATGGATG
CCAGCGAGGGGACAAACTATACGTGCTGTAAGTTACAGAGACATGAATGGAACAAACATGGATGGTGTAA
CTGGTACAATATAGACCCCTGGATACAGTTGATGAATAGAACCCAAGCAAACTTGGCAGAAGGCCCTCCG
GCCAAGGAGTGCGCTGTGACTTGCAGGTACGATAAAGATGCTGACATCAACGTGGTCACCCAGGCCAGAA
ACAGGCCAACAACCCTGACCGGTTGCAAGAAAGGAAAAAATTTTTCTTTTGCGGGTACAGTTATAGAGGG
CCCATGTAATTTCAATGTTTCCGTGGAGGATATCTTGTATGGGGATCATGAGTGCGGCAGTTTGCTTCAG
GACACGGCTCTGTACCTAGTGGATGGAATGACCAACACTATAGAGAATGCCAGACAGGGAGCAGCGAGGG
TAACATCTTGGCTCGGGAGGCAACTCAGCACTGCCGGGAAGAGGTTGGAGGGTAGAAGCAAAACCTGGTT
TGGTGCCTATGCCCTATCGCCTTACTGTAATGTAACAAGCAAAATAGGGTACATATGGTACACTAACAAC
TGCACCCCGGCTTGCCTCCCCAAAAATACAAAGATAATAGGCCCCGGAAAATTTGACACTAACGCGGAAG
ACGGAAAGATTCTCCATGAGATGGGGGGTCACCTATCAGAATTTCTGCTGCTCTCTCTGGTTGTTCTGTC
TGACTTCGCCCCTGAAACAGCCAGCGCGTTATACCTCATTTTGCACTACATGATTCCTCAATCCCATGAA
GAACCTGAAGGCTGCGACACAAACCAGCTGAATCTAACAGTGGAACTCAGGACTGAAGACGTAATACCGT
CATCAGTCTGGAATGTTGGCAAATATGTGTGTGTTAGACCAGACTGGTGGCCATATGAAACCAAGGTGGC
TTTGTTATTTGAAGAGGCAGGACAGGTCGTAAAATTAGCCTTACGAGCGCTGAGGGATTTAACCAGGGTC
TGGAATAGCGCATCAACCACGGCATTCCTCATCTGCTTGATAAAAGTATTAAGAGGACAGATCGTGCAAG
GTGTGATATGGCTGCTACTAGTAACTGGGGCACAAGGCCGGCTAGCCTGCAAGGAAGATTACAGGTACGC
AATATCATCGACCAATGAGATAGGGCTACTCGGGGCCGAAGGTCTCACCACCACCTGGAAAGAATACAAC
CACGATTTGCAACTGAATGACGGGACCGTTAAGGCCATTTGCGTGGCAGGTTCCTTTAAAGTCATAGCAC
TTAATGTGGTCAGTAGGAGGTATTTGGCATCATTGCATAAGGAGGCTTCACTCACTTCCGTGACATTTGA
GCTCCTGTTCGACGGGACCAACCCATCAACTGAGGAAATGGGAGATGACTTCGGGTTCGGGCTGTGCCCG
TTCGATACGAGTCCTGTTGTCAAGGGAAAGTACAATACAACCTTGTTGAACGGTAGTGCTTTCTATCTTG
TCTGCCCAATAGGGTGGACGGGTGTCATAGAGTGCACAGCAGTGAGCCCAACAACTCTGAGAACAGAAGT
GGTAAAGACCTTCAGGAGAGACAAGCCCTTTCCGCACAGAATGGATTGTGCGACCACCACAGTGGAAAAT
GGAGATTTATTCTACTGTAAGTTGGGGGGCAACTGGACATGTGTGAAAGGTGAACCAGTGGTCTACACGG
GGGGGCTAGTAAAACAATGCAGATGGTGTGGCTTCGACTTCAATGAGCCCGACGGACTCCCGCACTACCC
CATAGGTAAGTGCATCTTGGTAAATGAGACAGGTTACAGAATAGTAGATTCAACGGACTGTAACAGAGAT
GGCGTTGTAATCAGCACAGATGGGAGTCATGAGTGCTTGATCGGTAACACAACTGTCAAGGTGCATGCAT
CAGATGAAAGACTGGGCCCTATGCCATGCAGACCCAAAGAGATTGTCTCTAGTGCAGGACCTGTAAGGAA
AACTTCCTGTACATTCAACTACGCAAAAACTTTGAAGAACAAGTACTATGAGCCCAGGGACAGCTACTTC
CAGCAATATATGCTTAAGGGCGAGTATCAGTACTGGTTTGACCTGGACGTGACTGACCGCCACTCAGATT
ACTTCGCAGAATTTGTCGTCTTGGTAGTGGTAGCACTGTTAGGAGGAAGATATGTCCTGTGGCTAATAGT
GACCTACATAGTTCTAACAGAACAACTCGCCGCTGGTTTACCATTGGGCCAGGGTGAGGTAGTGTTGATA
GGGAACTTAATTACCCACACAGACATTGAGGTCGTAGTATATTTCTTACTACTCTATTTGGTCATGAGGG
ATGAGCCTATAAAGAAATGGATACTGCTGCTGTTCCATGCTATGACTAACAATCCAGTCAAGACCATAAC
AGTGGCATTGCTTATGGTTAGTGGGGTTGCCAAGGGTGGAAAGATAGACGGCGGTTGGCAGCGGCTGCCA
GAGACCAGCTTTGACATCCAACTCGCGCTGACAGTTATAGTAGTCGCTGTGATGTTACTGGCAAAGAGAG
ATCCAACTACTGTCCCCTTGGTTATAACAGTGGCAACCCTGAGAACGGCTAAGATGACTAATGGACTTAG
CACGGATATAGCCATAGCTACAGTGTCAACAGCGTTGCTAACCTGGACCTACATTAGTGACTATTATAGA
TACAAGACTTGGCTACAGTACCTTATTAGCACAGTGACAGGTATCTTCTTAATAAGGGTACTGAAGGGAA
TAGGTGAGTTGGATTTACACACTCCAACCTTGCCATCTTACAGACCCCTCTTCTTCATTCTCGTGTACCT
CATTTCCACTGCAGTGGTAACAAGATGGAATCTGGACATAGCCGGATTGCTGTTGCAGTGTGTCCCAACC
CTTTTGATGGTTTTTACGATGTGGGCAGACATTCTCACCCTGATCCTCATACTGCCCACTTACGAGCTAA
CAAAACTATATTACCTCAAGGAAGTGAAGACTGGGGCAGAAAAGGGCTGGTTATGGAAGACCAACTTCAA
GAGGGTAAACGACATATACGAAGTTGACCAATCTGGTGAAGGGGTTTACCTTTTCCCGTCAAAACAAAAG
ACAAGTTCAATAACAGGTACCATGTTGCCATTGATCAAAGCCATACTCATCAGCTGCATCAGTAATAAGT
GGCAGTTCATATATCTATTGTACTTGATATTTGAAGTGTCTTACTACCTCCACAAGAAGATCATAGATGA
AATAGCAGGAGGGACCAACTTCATCTCAAGACTTGTAGCCGCTTTGATCGAAGCCAATTGGGCCTTTGAC
AACGAAGAAGTTAGGGGTTTAAAGAAGTTCTTCCTGTTGTCTAGTAGGGTTAAAGAACTGATCATCAAAC
ACAAAGTGAGGAATGAAGTAATGGTCCACTGGTTTGGTGACGAAGAGGTTTATGGGATGCCAAAGTTGGT
TGGCTTAGTCAAGGCAGCAACATTGAGTAAAAATAAACATTGTATTTTGTGCACCGTCTGTGAAGACAGA
GAGTGGAGAGGAGAAACCTGCCCAAAATGCGGGCGTTTTGGGCCACCAATGACCTGTGGTATGACCCTAG
CCGACTTTGAAGAAAAACATTATAAGAGGATCTTTTTTAGAGAGGATCAATCAGAAGGGCCGGTTAGAGA
GGAGTACGCAGGGTATCTGCAATATAGAGCCAGAGGGCAATTATTCCTGAGGAATCTCCCGGTGCTAGCA
ACAAAAGTCAAGATGCTCCTGGTCGGAAATCTTGGGACGGAGGTGGGAGACTTGGAACACCTTGGCTGGG
TCCTTAGGGGGCCTGCCGTTTGCAAGAAGGTTACCGAACATGAGAAATGCACCACATCCATAATGGACAA
ATTGACTGCTTTTTTCGGTGTTATGCCAAGGGGCACCACACCTAGAGCCCCTGTGAGATTCCCCACCTCT
CTCTTAAAGATAAGAAGGGGGTTGGAAACTGGCTGGGCGTACACACACCAAGGTGGCATTAGTTCAGTGG
ACCATGTCACTTGTGGGAAAGACTTGCTGGTATGTGACACTATGGGCCGGACAAGGGTCGTTTGCCAATC
AAATAATAAGATGACAGATGAGTCTGAGTATGGAGTTAAAACTGACTCCGGATGCCCGGAAGGAGCTAGG
TGTTATGTGTTCAACCCAGAGGCAGTTAACATATCAGGGACTAAAGGAGCCATGGTCCACTTACAAAAAA
CTGGAGGAGAATTCACCTGTGTGACAGCATCAGGAACTCCGGCCTTCTTTGATCTCAAGAACCTCAAAGG
CTGGTCAGGGCTACCGATATTTGAGGCATCAAGTGGAAGGGTAGTCGGCAGGGTCAAGGTCGGGAAGAAT
GAGGACTCTAAACCAACCAAGCTTATGAGTGGAATACAAACAGTCTCCAAAAGTACCACAGACTTGACAG
AAATGGTAAAGAAAATAACGACCATGAACAGGGGAGAATTCAGACAAATAACCCTTGCTACAGGTGCCGG
AAAAACCACGGAACTCCCTAGGTCAGTCATAGAAGAGATAGGGAGGCATAAGAGAGTCTTGGTCTTGATC
CCTCTGAGGGCGGCAGCAGAGTCAGTATACCAATATATGAGACAAAAACATCCAAGCATCGCATTTAACC
TGAGGATAGGGGAGATGAAGGAAGGGGACATGGCCACAGGGATAACCTATGCTTCATACGGTTACTTCTG
TCAGATGCCACAACCTAAGTTGCGAGCCGCGATGGTTGAGTACTCCTTCATATTTCTTGACGAGTACCAC
TGTGCCACCCCAGAACAATTGGCCATCATGGGAAAGATCCACAGATTTTCAGAGAACCTGCGGGTAGTAG
CCATGACCGCAACACCAGCAGGCACAGTAACAACCACAGGGCAGAAACACCCTATAGAAGAATTCATAGC
CCCAGAAGTGATGAAAGGGGAAGACTTAGGCTCAGAGTACTTGGACATTGCTGGACTAAAGATACCAGTA
GAGGAGATGAAGAGCAACATGCTGGTTTTTGTGCCCACTAGGAACATGGCGGTGGAGACAGCAAAGAAAT
TGAAAGCTAAGGGTTACAACTCAGGCTACTATTATAGTGGAGAGGATCCATCTAACCTGAGGGTGGTAAC
GTCGCAGTCCCCGTACGTGGTGGTGGCAACCAACGCGATAGAATCAGGTGTTACTCTCCCGGACTTGGAT
GTGGTTGTCGATACAGGGCTTAAGTGTGAAAAGAGAATACGGCTGTCACCTAAGATGCCCTTCATAGTGA
CGGGCCTGAAGAGAATGGCTGTCACGATTGGGGAACAAGCCCAGAGAAGGGGGAGAGTTGGGAGAGTAAA
GCCTGGGAGATACTACAGGAGTCAAGAAACTCCCGTTGGTTCTAAAGATTACCATTATGATCTACTGCAA
GCACAGAGGTACGGTATTGAAGATGGGATAAACATCACCAAATCCTTTAGAGAGATGAACTATGATTGGA
GCCTTTATGAGGAGGACAGTCTGATGATTACACAATTGGAAATCCTCAATAATTTGTTGATATCAGAAGA
ACTACCGATGGCAGTAAAAAATATAATGGCCAGGACTGACCACCCAGAACCAATTCAGCTGGCGTACAAC
AGCTACGAAACACAAGTGCCAGTGCTATTCCCAAAAATAAAGAATGGAGAGGTGACTGATAGTTACGATA
ACTATACCTTCCTCAACGCAAGAAAATTGGGGGATGATGTACCCCCTTACGTGTATGCCACAGAGGATGA
GGACTTAGCGGTAGAGCTACTGGGCTTAGACTGGCCAGACCCTGGAAACCAAGGAACCGTAGAGGCTGGC
AGAGCACTAAAACAAGTAGTTGGTCTATCAACAGCTGAGAATGCCCTGTTAGTAGCCTTATTCGGCTATG
TAGGATATCAGGCACTTTCAAAGAGGCATATACCAGTAGTCACAGATATATATTCAATTGAAGATCACAG
GTTGGAAGACACCACACACCTACAGTACGCCCCAAATGCTATCAAGACGGAGGGGAAGGAGACAGAATTG
AAGGAGCTAGCCCAGGGGGATGTGCAGAGATGTGTGGAAGCTATGACCAATTATGCAAGAGAGGGTATCC
AATTCATGAAGTCTCAGGCACTGAAGGTGAAAGAAACCCCCACTTACAAAGAGACAATGAACACTGTGAC
TGACTATGTAAAGAAATTCATGGAGGCGCTGGCAGACAGTAAAGAAGACATCTTAAGATATGGGTTGTGG
GGGACGCACACAGCCTTATATAAGAGCATCAGTGCCAGGCTTGGGAGTGAGACTGCGTTCGCTACCCTGG
TCGTGAAGTGGCTGGCATTTGGGGGGGAATCAATAGCAGACCATGTCAAACAAGCGGCCACAGACTTGGT
CGTCTACTATATCATCAACAGACCTCAGTTCCCAGGAGACACAGAGACACAACAGGAAGGAAGGAAATTT
GTGGCCAGCCTACTGGTCTCAGCTCTAGCTACTTACACATACAAAAGCTGGAATTACAATAATCTGTCCA
AGATAGTTGAACCGGCTTTGGCCACTCTGCCCTATGCCGCCACAGCTCTCAAACTATTCGCCCCCACTCG
ATTGGAGAGCGTTGTCATATTGAGTACCGCAATCTACAAGACCTACCTATCAATCAGGCGCGGAAAAAGC
GATGGTTTGCTAGGCACAGGGGTTAGTGCGGCTATGGAGATCATGTCACAAAATCCAGTATCCGTGGGCA
TAGCAGTCATGCTAGGGGTAGGGGCCGTGGCAGCCCACAATGCAATCGAGGCCAGTGAGCAGAAGAGAAC
ACTACTCATGAAAGTTTTTGTAAAGAACTTCTTGGACCAAGCAGCCACTGATGAATTAGTCAAGGAGAGT
CCTGAGAAAATAATAATGGCTTTGTTTGAAGCAGTGCAGACAGTCGGTAACCCTCTTAGACTAGTATACC
ACCTTTATGGAGTTTTCTATAAGGGGTGGGAGGCAAAAGAGTTGGCCCAAAGGACAGCCGGTAGGAACCT
TTTCACTTTGATAATGTTCGAGGCTGTGGAACTACTGGGAGTAGATAGTGAAGGAAAGATCCGCCAGCTA
TCAAGTAATTACATACTAGAGCTCCTGTATAAGTTCCGTGACAGTATCAAGTCTAGCGTGAGGGAGATGG
CAATCAGCTGGGCCCCTGCCCCTTTCAGCTGTGATTGGACACCGACGGATGACAGAATAGGGCTCCCCCA
AGACAATTTCCTCCAAGTGGAGACGAAATGCCCCTGTGGTTACAAGATGAAGGCAGTTAAGAATTGTGCT
GGAGAGCTGAGACTCTTGGAGGAGGAAGGCTCATTTCTCTGCAGAAATAAATTCGGGAGAGGTTCACGGA
ACTACAGGGTGACAAAATACTATGATGACAATCTATCAGAAATAAAGCCAGTGATAAGAATGGAAGGGCA
TGTGGAACTCTACTACAAGGGAGCCACCATCAAACTGGACTTCAACAACAGTAAAACAATACTGGCAACC
GATAAATGGGAGATTGATCACTCCACTCTGGTCAGGGTGCTCAAGAGGCACACAGGGGCTGGATATCATG
GGGCATACCTGGGCGAGAAACCGAACTACAAACATCTGATAGAGAGGGACTGTGCAACCATCACCAAAGA
TAAGGTTTGTTTTCTCAAAATGAAGAGAGGGTGTGCATTTACTTATGACTTATCCCTTCACAACCTTACC
CGACTGATTGAATTGGTACACAAGAATAACTTGGAAGACAAAGAGATTCCTGCTGTTACGGTTACAACCT
GGCTGGCTTACACGTTTGTAAATGAAGATATAGGGACCATAAAACCAGCCTTCGGGGAGAAAGTAACACC
GGAGATGCAGGAGGAAATAACCTTGCAGCCTGCTGTAGTGGTGGATACAACTGACGTGACCGTGACTGTG
GTAGGGGAAGCCCCTACTATGACTACAGGGGAGACTCCGACAGCGTTCACCAGCTCAGGTTCAGACCCGA
AAGGCCAACAAGTTTTAAAACTGGGGGTAGGTGAAGGCCAATACCCCGGGACTAATCCACAGAGGGCAAG
CCTGCACGAAGCCATACAAGGTGCAGATGAGAGACCCTCGGTGCTGATATTAGGGTCTGATAAAGCCACC
TCTAATAGAGTGAAAACTGCAAAGAATGTAAAGGTATACAGAGGCAGGGACCCACTAGAAGTGAGAGATA
TGATGAGGAGGGGAAAGATCCTGGTCATAGCCCTGTCTAGGGTTGATAATGCTCTATTGAAATTTGTTGA
CTACAAAGGCACCTTTCTAACTAGAGAGACCCTAGAGGCATTAAGTTTGGGTAGGCCTAAAAAGAAAAAC
ATAACCAAGGCAGAAGCGCAGTGGTTGCTGTGCCTCGAAGACCAAATGGAAGAGCTACCCGATTGGTTCG
CAGCCGGGGAACCCATTTTTCTAGAGGCTAACATTAAACATGACAGGTACCATCTGGTGGGGGATATAGC
TAATATCAAGGAAAAAGCCAAACAGTTGGGAGCTACAGACTCCACAAAGATATCTAAGGAGGTTGGTGCA
AAAGTGTATTCTATGAAACTGAGTAATTGGGTGATGCAAGAAGAAAATAAACAGGGCAACCTGACCCCCT
TGTTTGAAGAGCTCCTGCAACAGTGTCCACCCGGAGGCCAGAACAAAACTGCACATATGGTCTCTGCTTA
CCAACTAGCTCAAGGGAACTGGATGCCAACCAGCTGCCATGTTTTTATGGGGACCATATCTGCCAGGAGG
ACCAAGACCCATCCATATGAAGCATACGTCAAGTTAAGGGAGTTGGTAGAGGAACACAAGATGAAAACAT
TGTGTCCTGGATCAAGCCTGGGTAAGCACAACGAATGGATAATTGGTAAAATCAAATACCAGGGAAACCT
GAGGACCAAACACATGTTGAACCCCGGCAAGGTGGCAGAGCAACTGTGCAGAGAGGGACACAGACACAAT
GTGTATAACAAGACAATAGGCTCAGTAATGACAGCTACTGGTATCAGGTTGGAGAAGTTGCCCGTGGTTA
GGGCCCAGACAGACACAACCAACTTCCACCAAGCAATAAGGGATAAGATAGACAAGGAAGAGAACCTACA
AACCCCGGGTTTACATAAGAAACTAATGGAAGTTTTCAATGCATTGAAACGACCCGAGTTAGAGTCCTCC
TACGATGCCGTGGAATGGGAGGAACTGGAGAGAGGAATAAACAGGAAGGGTGCTGCTGGTTTCTTTGAAC
GCAAAAATATAGGGGAAATATTGGATTCAGAGAAAAACAAAGTCGAAGAGATTATTGACAATCTGAAAAA
AGGCAGAAACATCAAATACTATGAAACCGCGATCCCAAAGAATGAGAAGAGGGACGTCAATGATGACTGG
ACTGCTGGTGACTTCGTGGAAGAGAAGAAACCCAGAGTCATACAATACCCTGAAGCAAAAACAAGGCTGG
CCATCACCAAGGTGATGTATAAGTGGGTGAAGCAGAAGCCAGTAGTTATACCCGGGTATGAAGGGAAGAC
ACCTCTATTCCAAATTTTTGACAAAGTAAAGAAGGAATGGGATCAATTCCAAAATCCAGTGGCAGTGAGT
TTTGACACTAAGGCGTGGGACACCCAGGTAACCACAAAAGATTTGGAGTTGATAAAGGACATACAAAAGT
ACTATTTCAAGAAGAAATGGCATAAATTTATTGACACCCTGACCATGCACATGTCAGAAGTACCCGTAAT
CAGTGCTGATGGGGAAGTATACATAAGGAAAGGGCAAAGAGGCAGTGGACAACCTGACACAAGCGCAGGC
AATAGCATGCTAAATGTGTTAACAATGATTTACGCCTTCTGCGAGGCCACGGGAGTACCCTACAAGAGCT
TCGACAGGGTGGCAAAAATTCATGTGTGTGGGGATGATGGTTTCCTGATCACAGAAAGAGCTCTCGGTGA
GAAATTCGCGAGTAAGGGAGTCCAGATCCTATATGAAGCTGGGAAGCCCCAGAAGATCACTGAAGGGGAC
AAGATGAAAGTGGCCTACCAATTTGATGATATTGAGTTTTGCTCCCATACACCAATACAAGTAAGGTGGT
CAGATAACACTTCTAGTTACATGCCGGGGAGAAATACAACCACAATCCTGGCTAAAATGGCCACAAGGTT
AGATTCCAGTGGTGAGAGGGGTACCATAGCATATGAGAAAGCAGTAGCATTCAGCTTCCTGCTGATGTAC
TCCTGGAACCCACTAATCAGAAGGATCTGCTTACTGGTGCTATCAACTGAACTGCAAGTGAAACCAGGGA
AGTCAACCACTTACTACTATGAAGGGGACCCGATATCTGCCTACAAGGAAGTCATCGGCCACAATCTTTT
TGATCTTAAGAGAACAAGCTTCGAGAAGCTGGCCAAGTTAAATCTCAGCATGTCAGTACTCGGAGCCTGG
ACTAGACACACCAGTAAAAGACTACTACAAGACTGTGTCAATGTGGGTGTTAAAGAGGGCAACTGGCTAG
TTAATGCAGATAGACTAGTAAGTAGCAAGACTGGAAATAGGTACATACCCGGAGAGGGCCACACCCTGCA
AGGGAGACATTATGAAGAACTGGTGTTGGCAAGAAAACAGATCAACAACTTTCAAGGGACCGACAGGTAC
AATCTAGGCCCAATAGTCAATATGGTGTTAAGGAGGCTGAGAGTCATGATGATGACCCTGATAGGGAGAG
GGGTATG
  • Protein Sequence : Show Sequence 
    >NP_075354.1 polyprotein [Classical swine fever virus]
MELNHFELLYKTNKQKPMGVEEPVYDATGRPLFGDPSEVHPQSTLKLPHDRGRGNIKTTLKNLPRKGDCR
SGNHLGPVSGIYVKPGPVFYQDYMGPVYHRAPLEFFNEAQFCEVTKRIGRVTGSDGKLYHIYVCIDGCIL
LKLAKRDEPRTLKWIRNFTDCPLWVTSCSDDGASGSKEKKPDRINKGKLKIAPKEHEKDSRTKPPDATIV
VEGVKYQVKKKGKVKGKSTQDGLYHNKNKPPESRKKLEKALLAWAVIAIMLYQPVEAENITQWNLSDNGT
NGIQHAMYLRGVSRSLHGIWPEKICKGVPTYLATDTELKEIQGMMDASEGTNYTCCKLQRHEWNKHGWCN
WYNIDPWIQLMNRTQANLAEGPPAKECAVTCRYDKDADINVVTQARNRPTTLTGCKKGKNFSFAGTVIEG
PCNFNVSVEDILYGDHECGSLLQDTALYLVDGMTNTIENARQGAARVTSWLGRQLSTAGKRLEGRSKTWF
GAYALSPYCNVTSKIGYIWYTNNCTPACLPKNTKIIGPGKFDTNAEDGKILHEMGGHLSEFLLLSLVVLS
DFAPETASALYLILHYMIPQSHEEPEGCDTNQLNLTVELRTEDVIPSSVWNVGKYVCVRPDWWPYETKVA
LLFEEAGQVVKLALRALRDLTRVWNSASTTAFLICLIKVLRGQIVQGVIWLLLVTGAQGRLACKEDYRYA
ISSTNEIGLLGAEGLTTTWKEYNHDLQLNDGTVKAICVAGSFKVIALNVVSRRYLASLHKEASLTSVTFE
LLFDGTNPSTEEMGDDFGFGLCPFDTSPVVKGKYNTTLLNGSAFYLVCPIGWTGVIECTAVSPTTLRTEV
VKTFRRDKPFPHRMDCATTTVENGDLFYCKLGGNWTCVKGEPVVYTGGLVKQCRWCGFDFNEPDGLPHYP
IGKCILVNETGYRIVDSTDCNRDGVVISTDGSHECLIGNTTVKVHASDERLGPMPCRPKEIVSSAGPVRK
TSCTFNYAKTLKNKYYEPRDSYFQQYMLKGEYQYWFDLDVTDRHSDYFAEFVVLVVVALLGGRYVLWLIV
TYIVLTEQLAAGLPLGQGEVVLIGNLITHTDIEVVVYFLLLYLVMRDEPIKKWILLLFHAMTNNPVKTIT
VALLMVSGVAKGGKIDGGWQRLPETSFDIQLALTVIVVAVMLLAKRDPTTVPLVITVATLRTAKMTNGLS
TDIAIATVSTALLTWTYISDYYRYKTWLQYLISTVTGIFLIRVLKGIGELDLHTPTLPSYRPLFFILVYL
ISTAVVTRWNLDIAGLLLQCVPTLLMVFTMWADILTLILILPTYELTKLYYLKEVKTGAEKGWLWKTNFK
RVNDIYEVDQSGEGVYLFPSKQKTSSITGTMLPLIKAILISCISNKWQFIYLLYLIFEVSYYLHKKIIDE
IAGGTNFISRLVAALIEANWAFDNEEVRGLKKFFLLSSRVKELIIKHKVRNEVMVHWFGDEEVYGMPKLV
GLVKAATLSKNKHCILCTVCEDREWRGETCPKCGRFGPPMTCGMTLADFEEKHYKRIFFREDQSEGPVRE
EYAGYLQYRARGQLFLRNLPVLATKVKMLLVGNLGTEVGDLEHLGWVLRGPAVCKKVTEHEKCTTSIMDK
LTAFFGVMPRGTTPRAPVRFPTSLLKIRRGLETGWAYTHQGGISSVDHVTCGKDLLVCDTMGRTRVVCQS
NNKMTDESEYGVKTDSGCPEGARCYVFNPEAVNISGTKGAMVHLQKTGGEFTCVTASGTPAFFDLKNLKG
WSGLPIFEASSGRVVGRVKVGKNEDSKPTKLMSGIQTVSKSTTDLTEMVKKITTMNRGEFRQITLATGAG
KTTELPRSVIEEIGRHKRVLVLIPLRAAAESVYQYMRQKHPSIAFNLRIGEMKEGDMATGITYASYGYFC
QMPQPKLRAAMVEYSFIFLDEYHCATPEQLAIMGKIHRFSENLRVVAMTATPAGTVTTTGQKHPIEEFIA
PEVMKGEDLGSEYLDIAGLKIPVEEMKSNMLVFVPTRNMAVETAKKLKAKGYNSGYYYSGEDPSNLRVVT
SQSPYVVVATNAIESGVTLPDLDVVVDTGLKCEKRIRLSPKMPFIVTGLKRMAVTIGEQAQRRGRVGRVK
PGRYYRSQETPVGSKDYHYDLLQAQRYGIEDGINITKSFREMNYDWSLYEEDSLMITQLEILNNLLISEE
LPMAVKNIMARTDHPEPIQLAYNSYETQVPVLFPKIKNGEVTDSYDNYTFLNARKLGDDVPPYVYATEDE
DLAVELLGLDWPDPGNQGTVEAGRALKQVVGLSTAENALLVALFGYVGYQALSKRHIPVVTDIYSIEDHR
LEDTTHLQYAPNAIKTEGKETELKELAQGDVQRCVEAMTNYAREGIQFMKSQALKVKETPTYKETMNTVT
DYVKKFMEALADSKEDILRYGLWGTHTALYKSISARLGSETAFATLVVKWLAFGGESIADHVKQAATDLV
VYYIINRPQFPGDTETQQEGRKFVASLLVSALATYTYKSWNYNNLSKIVEPALATLPYAATALKLFAPTR
LESVVILSTAIYKTYLSIRRGKSDGLLGTGVSAAMEIMSQNPVSVGIAVMLGVGAVAAHNAIEASEQKRT
LLMKVFVKNFLDQAATDELVKESPEKIIMALFEAVQTVGNPLRLVYHLYGVFYKGWEAKELAQRTAGRNL
FTLIMFEAVELLGVDSEGKIRQLSSNYILELLYKFRDSIKSSVREMAISWAPAPFSCDWTPTDDRIGLPQ
DNFLQVETKCPCGYKMKAVKNCAGELRLLEEEGSFLCRNKFGRGSRNYRVTKYYDDNLSEIKPVIRMEGH
VELYYKGATIKLDFNNSKTILATDKWEIDHSTLVRVLKRHTGAGYHGAYLGEKPNYKHLIERDCATITKD
KVCFLKMKRGCAFTYDLSLHNLTRLIELVHKNNLEDKEIPAVTVTTWLAYTFVNEDIGTIKPAFGEKVTP
EMQEEITLQPAVVVDTTDVTVTVVGEAPTMTTGETPTAFTSSGSDPKGQQVLKLGVGEGQYPGTNPQRAS
LHEAIQGADERPSVLILGSDKATSNRVKTAKNVKVYRGRDPLEVRDMMRRGKILVIALSRVDNALLKFVD
YKGTFLTRETLEALSLGRPKKKNITKAEAQWLLCLEDQMEELPDWFAAGEPIFLEANIKHDRYHLVGDIA
NIKEKAKQLGATDSTKISKEVGAKVYSMKLSNWVMQEENKQGNLTPLFEELLQQCPPGGQNKTAHMVSAY
QLAQGNWMPTSCHVFMGTISARRTKTHPYEAYVKLRELVEEHKMKTLCPGSSLGKHNEWIIGKIKYQGNL
RTKHMLNPGKVAEQLCREGHRHNVYNKTIGSVMTATGIRLEKLPVVRAQTDTTNFHQAIRDKIDKEENLQ
TPGLHKKLMEVFNALKRPELESSYDAVEWEELERGINRKGAAGFFERKNIGEILDSEKNKVEEIIDNLKK
GRNIKYYETAIPKNEKRDVNDDWTAGDFVEEKKPRVIQYPEAKTRLAITKVMYKWVKQKPVVIPGYEGKT
PLFQIFDKVKKEWDQFQNPVAVSFDTKAWDTQVTTKDLELIKDIQKYYFKKKWHKFIDTLTMHMSEVPVI
SADGEVYIRKGQRGSGQPDTSAGNSMLNVLTMIYAFCEATGVPYKSFDRVAKIHVCGDDGFLITERALGE
KFASKGVQILYEAGKPQKITEGDKMKVAYQFDDIEFCSHTPIQVRWSDNTSSYMPGRNTTTILAKMATRL
DSSGERGTIAYEKAVAFSFLLMYSWNPLIRRICLLVLSTELQVKPGKSTTYYYEGDPISAYKEVIGHNLF
DLKRTSFEKLAKLNLSMSVLGAWTRHTSKRLLQDCVNVGVKEGNWLVNADRLVSSKTGNRYIPGEGHTLQ
GRHYEELVLARKQINNFQGTDRYNLGPIVNMVLRRLRVMMMTLIGRGV
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A E2 mutant in Classical swine fever virus is attenuated and provides protection in pigs after oronasal vaccination (not intradermal vaccination) against lethal challenge dose of CSFV strain Eystrup (Maurer et al., 2005).
  • Additional Molecule Role : Protective antigen
  • Related Vaccine(s): Classical Swine Fever Virus DNA Vaccine pcDNA/E2 with TRIF , Classical swine fever virus DNA vaccine pCI-gp55 , Classical swine fever virus E2 mutant vaccine , DNA vaccine expressing the E2 protein , rORFV-CSFV-E2
6. E2
  • Gene Name : E2
  • Sequence Strain (Species/Organism) : Classical swine fever virus strain Shimen
  • NCBI Protein GI : 221063268
  • Other Database IDs : CDD:292945
  • Taxonomy ID : 11096
  • Gene Strand (Orientation) : ?
  • Protein Name : E2 glycoprotein
  • Protein pI : 5.93
  • Protein Weight : 38594.42
  • Protein Length : 447
  • Protein Note : highly virulent group I strain
  • Protein Sequence : Show Sequence 
    >ACL98471.1 E2 glycoprotein, partial [Classical swine fever virus]
RLACKEDYRYAISSTNEIGPLGAGGLTTTWKEYSHDLQLYDGTVKAICVAGSFKVTALNVVSRRYLASLH
KGALLTSVTFELLFDGTNPSTEEMGDDFGFGLCPFDTSPVVKGKYNTTLLNGSAFYLVCPIGWTGVIECT
AVSPTTLRTEVVKTFRREKPFPHRMDCVTTTVENEDLFYCKLGGNWTCVKGEPVVYTGGQVKQCKWCGFD
FNEPDGLPHYPIGKCILANETGYRIVDSTDCNRDGVVISAEGSHECLIGNTTVKVHASDERLGPMPCRPK
EIVSSAGPVRKTSCTFNYAKTLKNKYYEPRDSYFQQYMLKGEYQYWFDLDVTDRHSDYFAEFVVLVVVAL
LGGRYVLWLIVTYIVLTEQLAAG
  • Molecule Role : Protective antigen
7. gp55
  • Gene Name : gp55
  • VO ID : VO_0010899
  • NCBI Protein GI : 1763691
  • Other Database IDs : CDD:292945
  • Taxonomy ID : 11096
  • Gene Strand (Orientation) : ?
  • Protein Name : glycoprotein
  • Protein pI : 6.6
  • Protein Weight : 38891.77
  • Protein Length : 452
  • Protein Note : Pestivirus envelope glycoprotein E2; pfam16329
  • Protein Sequence : Show Sequence 
    >AAB39835.1 glycoprotein, partial [Classical swine fever virus]
VQGVVWLLLVTGAQGRLACKEDYRYAISSTDEIGLLGAGGLTTTWKEYNHDLQLNDGTVKASCVAGSFKV
TALNVVSRRYLASLHKKALPISVTFELLFDGTNPSTEEMEDDLRSGLCPFDTSPVVKGKYNTTLLNGSAF
YLVCPIGWTGVIECTAVSPTTLRTEVVKTFRRDKPFPHRMDCVTTTVENEDLFYCKLGGNWTCVKGEPVV
YTGGVVKQCRWCGFDFDGPDGLPHYPIGKCILANETGYRIVDSTDCNRDGVVISTEGSHECLIGNTAVKV
HASDERLGPMPCRPKEIVSSAGPVMKTSCTFNYTKTLKNRYYEPRDSYFRQYMLKGEYQYWFDLDATDRH
SDYFAEFVVLVVVALLRGRYVLWLIVTYAVL
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia (Hulst et al., 1993).
  • Related Vaccine(s): Classical swine fever virus E1 protein vaccine
III. Vaccine Information
1. Bayovac CSF E2
a. Tradename:
Bayovac CSF E2
b. Manufacturer:
Bayer Leverkusen
c. Vaccine Ontology ID:
VO_0000951
d. Type:
Recombinant vector vaccine
e. Status:
Licensed
f. Host Species for Licensed Use:
Pig
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
Baculovirus recombinant E2 protein without emulsion(Moormann et al., 2000)
2. Classical Swine Fever Virus DNA Vaccine pcDNA/E2 with TRIF
a. Vaccine Ontology ID:
VO_0004524
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of E2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
pRK-TRIF (Wan et al., 2010)
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Co-delivery of the DNA vaccine pcDNA/E2 with the TRIF adjuvant enhanced the cellular, not humoral, immune responses induced by DNA vaccines in mice (Wan et al., 2010).
  • Challenge Protocol: All immunized pigs were intramuscularly challenged 2 weeks after the last immunization with 105 TCID50 highly virulent CSFV Shimen strain (Wan et al., 2010).
  • Efficacy: All pigs co-immunized with pcDNA/E2 + pRK-TRIF survived viral challenge., though two pigs in this groups had a slight fever but recovered with 1 or 3 days and the remaining pig in this group had no CSF signs (Wan et al., 2010).
h. Pig Response
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All immunized pigs were intramuscularly challenged 2 weeks after the last immunization with 105 TCID50 highly virulent CSFV Shimen strain (Wan et al., 2010).
  • Efficacy: All pigs co-immunized with pcDNA/E2 + pRK-TRIF survived viral challenge., though two pigs in this groups had a slight fever but recovered with 1 or 3 days and the remaining pig in this group had no CSF signs (Wan et al., 2010).
3. Classical swine fever virus DNA vaccine pCI-gp55
a. Vaccine Ontology ID:
VO_0004340
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Pig
e. Gene Engineering of E2
  • Type: DNA vaccine construction
  • Description: Vector pCI expressed the gp55/E2 gene from classical swine fever virus (CSFV) (Hammond et al., 2001).
  • Detailed Gene Information: Click here.
f. Vector:
pCI (Hammond et al., 2001)
g. Immunization Route
Intramuscular injection (i.m.)
h. Pig Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Following challenge with CSFV, 100% of weaned pigs and 75% pre-weaned piglets were protected from disease (Hammond et al., 2001).
4. Classical swine fever virus E(rns) mutant vaccine
a. Vaccine Ontology ID:
VO_0002952
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Pig
e. Gene Engineering of E(rns)
  • Type: Gene mutation
  • Description: This E(rns) mutant is from Classical swine fever virus (Sainz et al., 2008).
  • Detailed Gene Information: Click here.
f. Immunization Route
intranasal immunization
g. Pig Response
  • Persistence: An E(rns) mutant is attenuated in swine (Sainz et al., 2008).
  • Efficacy: An E(rns) mutant induces protection in swine from challenge with wild type CSVF (Sainz et al., 2008).
5. Classical swine fever virus E1 mutant vaccine
a. Vaccine Ontology ID:
VO_0002953
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Pig
e. Gene Engineering of E1
f. Immunization Route
intranasal immunization
g. Pig Response
6. Classical swine fever virus E1 protein vaccine
a. Vaccine Ontology ID:
VO_0011509
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Classical swine fever virus gp55 encoding E1
e. Gene Engineering of gp55
  • Type: Recombinant protein preparation
  • Description: A recombinant virus BacEl[-], which expressed El without a C-terminal TMR, generated a protein that was secreted from the cells. The fraction of this protein that was found to be cell associated had a slightly lower molecular mass (49 to 52 kDa) than wild-type El and remained endo H sensitive. The high-mannose units of the secreted protein were trimmed during transport through the exocytotic pathway to endo H-resistant glycans, resulting in a protein with a lower molecular mass (46 to 48 kDa) (Hulst et al., 1993).
  • Detailed Gene Information: Click here.
f. Vector:
Baculovirus vector
g. Immunization Route
Intramuscular injection (i.m.)
h. Pig Response
  • Vaccination Protocol: Groups of two specific-pathogen-free, 10- to 12-week-old pigs were inoculated intramuscularly with a double water-oil emulsion of immunoaffinity-purified El on day 0. Pigs 1, 2, 3, and 4 were inoculated with 20 ug of El, and pigs 6, 7, 8, and 9 were inoculated with 100 ug of El. After 28 days, pigs 3 and 4 were vaccinated again with 20 ug and pigs 8 and 9 were vaccinated with 100 ug of immunoaffinity-purified El. Pigs 5 and 10 (control pigs) were inoculated on day 0 with a double water-oil emulsion of SF900 medium from Sf21 cells infected with wild-type AcNPV and vaccinated again with the same inoculum on day 28 (Hulst et al., 1993).
  • Challenge Protocol: Pigs of all groups were challenged intranasally on day 42 with 100 50% lethal doses of HCV strain Brescia 456610, a challenge dose that, in unprotected pigs, leads to acute disease characterized by high fever and thrombocytopenia starting at days 3 to 5 and to death at days 7 to 11(Hulst et al., 1993).
  • Efficacy: Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia (Hulst et al., 1993).
7. Classical swine fever virus E2 mutant vaccine
a. Vaccine Ontology ID:
VO_0002954
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Pig
e. Gene Engineering of E2
  • Type: Gene mutation
  • Description: This E2 mutant is from Classical swine fever virus (Maurer et al., 2005).
  • Detailed Gene Information: Click here.
f. Immunization Route
Oronasal immunization
g. Pig Response
  • Persistence: An E2 mutant is attenuated in swine (Maurer et al., 2005).
  • Efficacy: An E2 mutant induced significant protection in swine from challenge with wild type CSFV (Maurer et al., 2005).
8. Classical swine fever virus vaccine VAC-E0
a. Vaccine Ontology ID:
VO_0011427
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Antigen
Classical swine fever virus envelope glycoprotein E0
e. Gene Engineering of E0
  • Type: Recombinant vector construction
  • Description: A 0.7-kbp fragment (corresponding to nucleotides 1114 to 1838 of CSFV Alfort Tu¨bingen which encompassed the coding sequence for all but 5 amino acids (aa) of CSFV E0 was isolated from plasmid pHCK11 by digestion with BglI and BanI. The missing codons were substituted for with synthetic adaptor oligonucleotides. The 59 adaptor BBA (59GATCCACCAT GGGGGCCCTGT39) linked the BglI site of the 0.7-kbp fragment to the BamHI site of pGS62 and contained a sequence according to Kozak’s rules. Besides the initial methionine, BBA coded for 3 aa: glycine (not found in the CSFV sequence) and alanine and leucine (corresponding to CSFV aa 250 and 251). The 39 adaptor BEA (59GTGCCTATGCCTGAGTTA39) connected the BanI site of the 0.7-kbp fragment to the EcoRI site of pGS62 and encoded amino acids corresponding to glycine 491 to alanine 494 of CSFV as well as a stop codon. After ligation with adaptors BBA and BEA, the 0.7-kbp fragment was introduced into recombination vector pGS62 to derive plasmid pGS62-E0 (König et al., 1995). To generate a VVR vaccine, CVI cells were infected with vaccinia virus strain WR (VAC-WR) at a multiplicity of infection (MOI) of 0.05 and after 1 h were transfected with the respective recombination plasmids by using a mammalian transfection kit. After 48 h of incubation, virus progeny was harvested by repeated freezing and thawing. Selection for a thymidine kinase-negative phenotype on human 143tk2 cells was carried out with medium containing 1% agarose and 100 mg of bromodeoxyuridine per ml. VVR were isolated from thymidine kinase negative virus plaques and were plaque purified twice (König et al., 1995).
  • Detailed Gene Information: Click here.
f. Vector:
Recombinant Vaccinia Virus
g. Immunization Route
Intradermal injection (i.d.)
h. Pig Response
  • Vaccination Protocol: Pigs were vaccinated with a single dose of VVR (VAC-E0 or VAC-E2) or control strain VAC-WR by three different routes simultaneously (intradermally, intraperitoneally, and intravenously). A total of 5 x 107 PFU of VVR was given by each route. Clinical reactions after vaccination were monitored by daily examination (König et al., 1995).
  • Challenge Protocol: The pigs were challenged intranasally 5 weeks after immunization with 2 x 107 50% tissue culture infective doses of CSFV Alfort Tu¨bingen. Clinical symptoms were monitored daily. Blood samples were taken at days 5 and 12 postinfection (p.i.) and at the slaughter of the animals (days 12 to 27 p.i.) (König et al., 1995).
  • Efficacy: Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).
9. Classical swine fever virus vaccine VAC-E2
a. Vaccine Ontology ID:
VO_0011508
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Antigen
Classical swine fever virus E2
e. Gene Engineering of E2
  • Type: Recombinant vector construction
  • Description: A 1.5-kbp DNA fragment (representing nucleotides 2433 to 3971 of CSFV Alfort Tu¨bingen) isolated from clone pHCK11 by NheI-HpaI digestion was ligated into plasmid pBR02-16/4. The resulting construct contained the nucleotide sequences for CSFV E2 and PRV-SP. Isolation of the PRV-SP E2 sequence and introduction into vector pGS62 gave rise to pGS62-E2 (König et al., 1995).
  • Detailed Gene Information: Click here.
f. Vector:
Recombinant Vaccinia Virus
g. Immunization Route
Intradermal injection (i.d.)
h. Pig Response
  • Vaccination Protocol: Pigs were vaccinated with a single dose of VVR (VAC-E0 or VAC-E2) or control strain VAC-WR by three different routes simultaneously (intradermally, intraperitoneally, and intravenously). A total of 5 x 107 PFU of VVR was given by each route. Clinical reactions after vaccination were monitored by daily examination (König et al., 1995).
  • Challenge Protocol: The pigs were challenged intranasally 5 weeks after immunization with 2 x 107 50% tissue culture infective doses of CSFV Alfort Tu¨bingen. Clinical symptoms were monitored daily. Blood samples were taken at days 5 and 12 postinfection (p.i.) and at the slaughter of the animals (days 12 to 27 p.i.) (König et al., 1995).
  • Efficacy: Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).
10. DNA vaccine expressing the E2 protein
a. Vaccine Ontology ID:
VO_0004514
b. Type:
Live, attenuated vaccine
c. Status:
Licensed
d. Gene Engineering of E2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
pcDNA3.1+ (Tarradas et al., 2011)
f. Immunization Route
Intramuscular injection (i.m.)
g. Pig Response
  • Vaccination Protocol: Groups of 3 pigs were used in each experimental group. Briefly, group 1 (pE2) was inoculated with 500 μg of plasmid pE2 in co-injection with 500 μg of pcDNA3.1 (empty plasmid, Invitrogen), group 2 (pE2 + pCCL20) was inoculated with 500 μg pE2 in co-injection with 500 μg of pCCL20, and the control group was injected with PBS. In all cases, three doses were administered intramuscularly in the neck every 12 days. Before every immunization (at days 0, 12 and 24), pigs were bled to follow the CSFV specific immunoresponse (Tarradas et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The vaccine is able to increase antibody-mediated responses, while enhancing the T helper cell response associated with the induction of neutralizing antibodies against CSFV (Tarradas et al., 2011).
  • Challenge Protocol: Thirty-six days after the first immunization (pre-challenge), all pigs were challenged with 105 DICT50 of CSFV virulent Margarita strain by i.m. injection in the neck (Tarradas et al., 2011).
  • Efficacy: Immunized animals with E2 DNA vaccine in co-administration with the plasmid containing swine CCL20 developed high titers of neutralizing antibodies against homologous and heterologous CSFV strains, and were totally protected upon a lethal viral challenge (Tarradas et al., 2011).
11. Porcilis Pesti
a. Tradename:
Porcilis Pesti
b. Manufacturer:
Intervet
c. Vaccine Ontology ID:
VO_0000981
d. Type:
Recombinant vector vaccine
e. Status:
Licensed
f. Host Species for Licensed Use:
Pig
g. Immunization Route
Intramuscular injection (i.m.)
h. Description
Baculovirus recombinant E2 protein without emulsion(van, 2003)
12. rAdV-SFV-E2
a. Vaccine Ontology ID:
VO_0004700
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Pig
e. Preparation
An adenovirus-vectored Semliki forest virus replicon construct expressing the E2 glycoprotein from CSFV, rAdV-SFV-E2 (Sun et al., 2013).
f. Immunization Route
Intramuscular injection (i.m.)
g. Pig Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Two immunizations with a dose as low as 6.25×105 TCID(50) or a single immunization with a dose of 107 TCID(50) rAdV-SFV-E2 provided complete protection against a lethal CSFV challenge (Sun et al., 2013).
13. rORFV-CSFV-E2
a. Vaccine Ontology ID:
VO_0004768
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of E2
  • Type: Recombinant vector construction
  • Description: Using the new recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E. (Voigt et al., 2007).
  • Detailed Gene Information: Click here.
f. Preparation
(Voigt et al., 2007) the recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E2 glycoprotein to protect CSFV chellange.
g. Immunization Route
Intramuscular injection (i.m.)
h. Pig Response
  • Vaccination Protocol: Pigs were vaccinated with ORFV (Voigt et al., 2007).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Pigs were challenged with CSFV (Voigt et al., 2007).
  • Efficacy: Vector virus vaccinated swine were able to cope with the lymphocyte and in particular B-cell depression in peripheral blood after challenge showing no clinical signs and no viremia. Also, the vaccinated swine demonstrated that a single intra-muscular application confers solid protection (Voigt et al., 2007).
14. rPFV-CSFV-E0
a. Vaccine Ontology ID:
VO_0004748
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
CSFV E0 gene was amplified from the plasmid pMD18-T-E0 by PCR and cloned into the FPV-P11 and FPV-pSY (Wang et al., 2008).
f. Immunization Route
Intramuscular injection (i.m.)
g. Pig Response
  • Vaccination Protocol: Piglets were immunized three times with recombinant Fowlpox virus (Wang et al., 2008).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The pigs were challenged with CSFV (Wang et al., 2008).
  • Efficacy: The protection experiment showed that 75% of piglets immunized three times with recombinant Fowlpox virus were survived, indicating that the recombinant Fowlpox virus was effective (Wang et al., 2008).
IV. References
1. Fernandez-Sainz et al., 2009: Fernandez-Sainz I, Holinka LG, Gavrilov BK, Prarat MV, Gladue D, Lu Z, Jia W, Risatti GR, Borca MV. Alteration of the N-linked glycosylation condition in E1 glycoprotein of Classical Swine Fever Virus strain Brescia alters virulence in swine. Virology. 2009; 386(1); 210-216. [PubMed: 19203774].
2. Hammond et al., 2001: Hammond JM, Jansen ES, Morrissy CJ, Goff WV, Meehan GC, Williamson MM, Lenghaus C, Sproat KW, Andrew ME, Coupar BE, Johnson MA. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Veterinary microbiology. 2001; 80(2); 101-119. [PubMed: 11295331].
3. Hulst et al., 1993: Hulst MM, Westra DF, Wensvoort G, Moormann RJ. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. Journal of virology. 1993; 67(9); 5435-5442. [PubMed: 8350404].
4. König et al., 1995: König M, Lengsfeld T, Pauly T, Stark R, Thiel HJ. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. Journal of virology. 1995; 69(10); 6479-6486. [PubMed: 7666549].
5. Lin et al., 2009: Lin GJ, Liu TY, Tseng YY, Chen ZW, You CC, Hsuan SL, Chien MS, Huang C. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune response. Veterinary microbiology. 2009; 139(3-4); 369-374. [PubMed: 19625145].
6. Maurer et al., 2005: Maurer R, Stettler P, Ruggli N, Hofmann MA, Tratschin JD. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine. 2005; 23(25); 3318-3328. [PubMed: 15837238].
7. Moormann et al., 2000: Moormann RJ, Bouma A, Kramps JA, Terpstra C, De Smit HJ. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Veterinary microbiology. 2000; 73(2-3); 209-219. [PubMed: 10785329].
8. Sainz et al., 2008: Sainz IF, Holinka LG, Lu Z, Risatti GR, Borca MV. Removal of a N-linked glycosylation site of classical swine fever virus strain Brescia Erns glycoprotein affects virulence in swine. Virology. 2008; 370(1); 122-129. [PubMed: 17904607].
9. Sun et al., 2013: Sun Y, Tian DY, Li S, Meng QL, Zhao BB, Li Y, Li D, Ling LJ, Liao YJ, Qiu HJ. Comprehensive evaluation of the adenovirus/alphavirus-replicon chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever. Vaccine. 2013; 31(3); 538-544. [PubMed: 23153441].
10. Tarradas et al., 2011: Tarradas J, Álvarez B, Fraile L, Rosell R, Muñoz M, Galindo-Cardiel I, Domingo M, Dominguez J, Ezquerra A, Sobrino F, Ganges L. Immunomodulatory effect of swine CCL20 chemokine in DNA vaccination against CSFV. Veterinary immunology and immunopathology. 2011; 142(3-4); 243-251. [PubMed: 21684019].
11. van, 2003: van Aarle P. Suitability of an E2 subunit vaccine of classical swine fever in combination with the E(rns)-marker-test for eradication through vaccination. Developments in biologicals. 2003; 114; 193-200. [PubMed: 14677689].
12. Voigt et al., 2007: Voigt H, Merant C, Wienhold D, Braun A, Hutet E, Le Potier MF, Saalmüller A, Pfaff E, Büttner M. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine. 2007; 25(31); 5915-5926. [PubMed: 17600594].
13. Wan et al., 2010: Wan C, Yi L, Yang Z, Yang J, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Veterinary immunology and immunopathology. 2010; 137(1-2); 47-53. [PubMed: 20466439].
14. Wang et al., 2008: Wang YH, Li PH, Zhang MT, Zhang YM. [Construction of recombinant fowlpox virus expressing E0 gene of classical swine fever virus shimen strain and the animal immunity experiment]. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui]. 2008; 24(1); 59-63. [PubMed: 18320824].
15. Wiki: Classical swine fever: Classical swine fever [http://en.wikipedia.org/wiki/Classical_swine_fever_virus]